https://www.selleckchem.com/pr....oducts/ll37-human.ht
Neoadjuvant endocrine therapy is not the standard of care for breast cancer primarily because the optimal treatment duration remains unclear. This phase 2 prospective multicenter study analyzed time to progression, time to maximal response, and time to treatment failure of neoadjuvant exemestane. Inclusion criteria were women aged ≥ 60 years with Stage II or III breast cancer classified as estrogen receptor-positive / human epidermal growth factor receptor 2-negative. Response was defined as a ≥ 10% (minimum of 3 mm) decrease in tumo
Like
Comment
Share
